We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

MRK
Merck & Co. Inc.
NYSE
People also watch : PFE JNJ BMY LLY PG
58.66 0.23 (0.39%)

After hours: 58.57-0.09 (-0.15%) as of 7:51 PM EDT

Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Prev Close 58.43
Open 59.01
Bid 58.42 x 200
Ask 58.57 x 600
52wk Range 45.69 - 60.07
Day's Range 58.27 - 59.20
Volume 8,090,562
Avg Vol (3m) 8,728,371
As of 4:00 PM EDT. Market closed.
  • ExxonMobil slides, Amazon and Alphabet jump
    Editor's Pick
    Yahoo Finance 2 days ago

    ExxonMobil slides, Amazon and Alphabet jump

    ExxonMobil (XOM) shares fell in early trading. Amazon (AMZN) stock got a nice pop in early trading. The delivered earnings per share for UPS (UPS) came in right in line with forecasts for the second quarter, while revenue was a tad shy of estimates.

  • US economy still in a funk, new study reveals Clinton is more bullish than Trump
    Editor's Pick
    Yahoo Finance 2 days ago

    US economy still in a funk, new study reveals Clinton is more bullish than Trump

    Stocks started the day mixed (^DJI, ^GSPC, ^IXIC) as investors weighed disappointing figures on second-quarter economic growth, an earnings miss from ExxonMobil (XOM) and stronger than expected results from Amazon (AMZN) and Alphabet (GOOGL). Meanwhile, oil prices (CL=F) remain in the red, with crude on track for its biggest monthly loss this year on nagging oversupply worries. Gross domestic product grew at a seasonally adjusted annual rate of 1.2% in the second quarter, according the Commerce Department. ExxonMobil (XOM) shares fell in early trading.

  • The Wall Street Journal 22 hours ago

    [$$] Earnings Watch

    A roundup of news items about corporate earnings.

  • Merck posts strong 2Q numbers, while building for long term
    Associated Press yesterday

    Merck posts strong 2Q numbers, while building for long term

    Drugmaker Merck & Co., focused heavily on its long-term future as it builds sales of crucial new medicines Keytruda for cancer and Zepatier for hepatitis C, still posted a big jump in second-quarter profit ...

  • AbbVie, Merck Beat Earnings Estimates, But Sanofi Lags
    Investor's Business Daily yesterday

    AbbVie, Merck Beat Earnings Estimates, But Sanofi Lags

    Big U.S. pharmas AbbVie and Merck traded higher and flat, respectively, after reporting positive Q2 results, while France's Sanofi headed lower.

  • Forbes yesterday

    Merck Results Underscore Need To Go Big Or Go Home In Diabetes Market

    Looking at the earnings posted by Merck & Co. (MRK), I could not help but compare and contrast them with what Sanofi (SNY) said this morning. Like Sanofi had with Lantus, Merck has a mega-blockbuster with Januvia. Just as Lantus was getting long in the tooth and facing patent expiration